# A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19

> **NCT04627584** · PHASE2 · UNKNOWN · sponsor: **Mabwell (Shanghai) Bioscience Co., Ltd.** · enrollment: 150 (estimated)

## Conditions studied

- Covid19

## Interventions

- **COMBINATION_PRODUCT:** MW33 injection
- **COMBINATION_PRODUCT:** MW33 injection placebo

## Key facts

- **NCT ID:** NCT04627584
- **Lead sponsor:** Mabwell (Shanghai) Bioscience Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-12-29
- **Primary completion:** 2021-05
- **Final completion:** 2021-09
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2021-02-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04627584

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04627584, "A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04627584. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*